cabozantinib,atezolizumab
roche
['cabo ', 'contact-03', 'rcc,(-irccs),(-srcc),(-urcc)', 'atezo']
 rand phiii contact-03 adv #ccrcc/nccrcc post-ici (ici immediately preceding) cabo/atezo didn t improve pfs or os over cabo (orr 41% both), subgroups didn t identify pts who benefit from ici-rechallenge. although neg study, imp findings in era of #io #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope